Immune thrombocytopenia in severe neonatal infections

Tate, Douglas Y.; Carlton, Gregory T.; Johnson, Dana E.; Sorenson, Robert L.; Nesbit, Mark E.; White, James G.; Thompson, Theodore R.; Krivit, William

doi:10.1016/s0022-3476(81)80720-2

Cited by 48 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The technical dif culties associated with performing any of these tests in small, ill neonates, however, have forced neonatologists to rely on indirect measurements of the state of platelet production and consumption. In this regard, the mean platelet volume (7,14), plateletassociated immunoglobulin G (IgG) (7,15), reticulated platelet counts (16,17), 111 In-oxine-labeled platelet survival (18,19), and quanti cation of circulating megakaryocytes and their progenitors in the peripheral blood (20,21) have all been used to evaluate the kinetic mechanisms responsible for neonatal thrombocytopenia. However, none of these techniques has ever been validated in neonates with the concomitant study of bone marrow thrombopoiesis.…”

Section: Thrombocytopenia: Kinetic Mechanismsmentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms underlying thrombocytopenia in the neonatal intensive care unit

Sola

Rimsza

2002

Acta Paediatrica

View full text Add to dashboard Cite

Sola MC, Rimsza LM. Mechanisms underlying thrombocytopenia in the neonatal intensive care unit. Acta Paediatr 2002; Suppl 438: 66-73. Stockholm. ISSN 0803-5326Thrombocytopenia is one of the most common hematological problems among neonates in the neonatal intensive care unit (NICU), but in the majority of cases the kinetic mechanism responsible is unclear. This review focuses on both traditional and innovative methods used to evaluate the mechanisms responsible for thrombocytopenia in neonates, and analyzes the data generated from those methods. Conclusion:Results of studies using new methods for evaluating thrombocytopenia, coupled with recent descriptions of marrow megakaryocyte mass, suggest that decreased platelet production complicates most cases of thrombocytopenia among neonates in the NICU.

show abstract

Section: Thrombocytopenia: Kinetic Mechanismsmentioning

confidence: 99%

“…Results of studies using these techniques have been con icting. While some have suggested that increased consumption of platelets accounts for most cases of thrombocytopenia (7,15,18), others have concluded that reduced platelet production is generally responsible (8,20).…”

Section: Thrombocytopenia: Kinetic Mechanismsmentioning

confidence: 99%

Mechanisms underlying thrombocytopenia in the neonatal intensive care unit

Sola

Rimsza

2002

Acta Paediatrica

View full text Add to dashboard Cite

show abstract

“…Thrombocytopenia, reported in 1-26% of cases, can cause bleeding in only very rare cases [1][2][3]. Thrombocytopenia related to systemic infections may be due to a variety of causes: hypersplenism, bone marrow suppression, disseminated intravascular coagulation, increased clearance, immune-mediated destruction, hemophagocytosis, and adherence to damaged vascular surfaces [4][5][6][7][8][9][10]. The data is presently insufficient regarding the management of Brucella-associated bleeding and the time for antimicrobial therapy to take effect [10,11].…”

Section: Introductionmentioning

confidence: 99%

Intravenous gamma globulin is effective as an urgent treatment in Brucella‐induced severe thrombocytopenic purpura

Altuntaş¹,

Yıldız²,

Sarı³

et al. 2005

American J Hematol

View full text Add to dashboard Cite

Severe thrombocytopenia is a rare hematologic manifestation of brucellosis, which can occasionally be associated with bleeding into the skin and from mucosal sites. Prompt recognition of this brucellosis complication and aggressive therapy is vital because the mortality rate associated with bleeding into the central nervous system is high. We report a case of a patient infected with Brucella melitensis who was admitted with a severe case of thrombocytopenic purpura. The patient responded well to intravenous gamma globulin (IVIg) treatment with platelet recovery within 2-3 days. For cases of Brucella-induced thrombocytopenic purpura, IVIg may be administered as an urgent therapy until the microbial therapy takes effect. Am.

show abstract

“…This type of thrombocytopenia is commonly rapidly progressive, severe (platelet nadir < 50 × 10 9 /l) and prolonged. Although DIC is often quoted as the mechanism of thrombocytopenia in neonatal sepsis, in our experience, and that of others, laboratory evidence of this is uncommon (Tate et al, 1981;Gross et al, 1982). In practice, DIC with resultant thrombocytopenia most commonly complicates birth asphyxia and necrotizing enterocolitis rather than infection (Gross et al, 1982).…”

Section: Diagnostic Approach To Thrombocytopenia In the Newbornmentioning

confidence: 53%